Findings seen among adult psychiatric inpatients taking an antipsychotic
FRIDAY, Sept. 20, 2024 (HealthDay News) – There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient”s risk for developing movement disorders while taking an antipsychotic, according to a study published in the April-June issue of Innovations in Clinical Neuroscience.
Carolyn O’Donnell, Pharm.D., from the Edward Hines Jr. Veterans Administration Hospital in Hines, Illinois, and colleagues investigated associations between patients taking antipsychotics with low HDL-C and the risk for developing a movement disorder. The analysis included 89 adult patients at an inpatient state psychiatric facility.
The researchers report that only eight patients had an Abnormal Involuntary Movement Scale score greater than 0 and HDL-C levels ranged from 17 mg/dL to 83 mg/dL. There was no statistically significant association seen when comparing a patient”s movement disorder, Abnormal Involuntary Movement Scale scores, and HDL-C levels.
“It is our hope that our research will support prioritized prescribing decisions focused more directly on removing offending medications, versus exploring hypothesized physiologic factors such as HDL-C, because earlier recognition of drug-induced movement disorders permits rapid intervention and decreased risk of permanently disfiguring and debilitating extrapyramidal symptoms,” the authors write.
Eating More Whole Grains Daily Linked to Cardiometabolic Benefits 
Considerable Gaps Identified in LDL Cholesterol Control 
Machine Learning LDL-C Equation Comparable to Original Martin-Hopkins 
Cardiovascular Risk Factors Linked to Increased Plaque Burden 
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus 
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD 
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status 
87.5 Million U.S. Adults Now Eligible for Statins Under New Guidelines .jpg)
